🟢 Connect Biopharma is trading 5.6% up in pre-market after completing Phase 2 enrollment

Connect Biopharma is trading 5.6% up in pre-market at $2.69 as investors continued reacting to its August 12 earnings update.

• Completed enrollment in both Phase 2 Seabreeze STAT studies; expects topline asthma and COPD results in September 2026.
• Cash runway extends at least one year.
• Update included $2.8 million in collaboration revenue and a new intravenous rademikibart study.